Compare ARCB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCB | IDYA |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 1994 | 2019 |
| Metric | ARCB | IDYA |
|---|---|---|
| Price | $154.30 | $35.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $122.75 | $52.86 |
| AVG Volume (30 Days) | 346.6K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,657,864,000.00 | $218,710,000.00 |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $5.80 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.56 | ★ 3024.43 |
| 52 Week Low | $59.43 | $22.09 |
| 52 Week High | $176.69 | $40.58 |
| Indicator | ARCB | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 51.56 |
| Support Level | $137.39 | $32.85 |
| Resistance Level | $176.69 | $38.17 |
| Average True Range (ATR) | 5.67 | 1.45 |
| MACD | 0.48 | -0.44 |
| Stochastic Oscillator | 67.92 | 24.20 |
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.